Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1028506 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1IDO1HTR7 | |
| SCHEMBL2673980 | 0.87 | TAAR1 (0.77) | TAAR1IDO1CYP2A6HTR6HRH3 | |
| SCHEMBL8096473 | 0.85 | TAAR1 (0.74) | TAAR1IDO1HRH3NOS1ACHE | |
| SCHEMBL29596752 | 0.85 | TAAR1 (0.74) | TAAR1IDO1HRH3NOS1ACHE | |
| Hydrochloric Acid SCHEMBL1028929 | 0.85 | TAAR1 (0.74) | TAAR1IDO1CYP2A6HTR6HRH3 | |
| SCHEMBL8605570 | 0.85 | TAAR1 (0.74) | TAAR1IDO1HRH3 | |
| SCHEMBL9848072 | 0.84 | TAAR1 (0.71) | TAAR1IDO1HRH3 | |
| SCHEMBL8502036 | 0.84 | TAAR1 (0.71) | TAAR1IDO1HRH3 | |
| SCHEMBL659100 | 0.83 | TAAR1 (0.70) | TAAR1DRD2DRD1HTR7CYP2A6 | |
| SCHEMBL8092500 | 0.81 | TAAR1 (0.68) | TAAR1IDO1HRH3HTR2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2025029594-A2 | BROAD-WAVELENGTH OPTICAL RETARDATION THROUGH IN-PLANE OPTICAL ANISOTROPY OF SINGLE CRYSTALLINE MATERIALS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2025-02-06 | — | — | WO | claimed |
| CN-119192880-A | Preparation method of archaized pigment | 江苏众立生包装科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2024175957-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | claimed |
| CN-117946370-A | Ester bond curing agent, degradable epoxy resin and preparation of composite material thereof | 四川大学 | 2024-04-30 | — | — | CN | claimed |
| EP-4313943-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200208-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | WO | claimed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | claimed |
| EP-2205573-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| WO-2009043780-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| EP-1450796-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| EP-1450796-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-01 | — | — | EP | claimed |
| US-6596718-B1 | A compound of formula I has a good affinity to the A2A receptor and is useful for the treatment of diseases mediated by this receptor. | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | claimed |
| WO-2003045385-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | HPD, DDT, PPOX | TAAR1 3744/4885DRD2 362/4885DRD1 277/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | TAAR1 4762/4885DRD2 3882/4885DRD1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.